logo

For the Inventor, By the Inventor

Dueren, Germany

Sven Kuehnert

This inventor holds 16 USPTO granted patents and 30 published patent applications, plus 2 CIPO patents. Top assignees: Gruenenthal Gmbh, Grunenthal Gmbh. Active years: 2007-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sven Kuehnert. Retrieved from https://idiyas.com/inventor/sven-kuehnert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 

% Patents Active = 37.5

 

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 55(Granted Patents)


Company Filing History:

goldMedal13 out of 361 
 
Gruenenthal Gmbh
 patents
silverMedal3 out of 107 
 
Grunenthal Gmbh
 patents

Years Active: 2007-2020

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 10829480 - 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives (2020-11-10),
2. 10807989 - 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives (2020-10-20),
3. 10807988 - 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives (2020-10-20),
4. 10793556 - 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives (2020-10-06),
5. 10793528 - 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives (2020-10-06),
6. 10214520 - Substituted azaspiro(4.5)decane derivatives (2019-02-26),
7. 9108936 - Substituted 4-aminobenzamides as KCNQ2/3 modulators (2015-08-18),
8. 8288424 - Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions (2012-10-16),
9. 8084470 - Substituted nicotinamide compounds and uses thereof (2011-12-27),
10. 8017772 - Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain (2011-09-13),
11. 7893069 - Substituted imidazo[2,1-b]thiazole compounds and uses thereof (2011-02-22),
12. 7879858 - Substituted tetrahydropyrrolopyrazine compounds and the use thereof in pharmaceutical compositions (2011-02-01),
13. 7625900 - Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain (2009-12-01),
14. 7541495 - para-alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof (2009-06-02),
15. 7420056 - Substituted bicyclic imidazo-3-ylamine compounds (2008-09-02),

Title: Sven Kuehnert: Pioneering Innovations in Medicine

Introduction:

Sven Kuehnert, a visionary inventor hailing from Dueren, Germany, is a trailblazer in the field of pharmaceutical innovations. With a keen passion for pushing the boundaries of technology and a relentless pursuit of excellence, Kuehnert continues to inspire the next generation of inventors worldwide.

Latest Patents:

Kuehnert's latest patents showcase his expertise in the pharmaceutical domain:

1. "3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives" - This invention pertains to novel derivatives with applications in medicine, particularly in the treatment of pain.

2. "3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives" - Another groundbreaking invention by Kuehnert that offers significant potential in the medical field.

Career Highlights:

During his illustrious career, Kuehnert has made significant contributions while working at renowned companies like Grünenthal GmbH. His dedication to innovation and his knack for problem-solving have earned him accolades within the industry.

Collaborations:

Kuehnert has had the privilege of collaborating with esteemed professionals in the field, including Wolfgang Schroeder and Klaus Schiene. This collaboration has led to the development of cutting-edge solutions that have left a lasting impact on the pharmaceutical landscape.

Conclusion:

In conclusion, Sven Kuehnert's innovative spirit and unwavering commitment to excellence underscore his position as a driving force in the field of pharmaceutical inventions. His groundbreaking work continues to shape the future of medicine, leaving an indelible mark on the industry and inspiring generations to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…